Literature DB >> 16989631

Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV development.

Michael R Betts1, Clive M Gray, Josephine H Cox, Guido Ferrari.   

Abstract

The definition of immune correlates of protection in HIV-1 infection is pivotal to the design of successful vaccine candidates and strategies. Although significant methodological and conceptual strides have been made in our understanding of HIV-specific cellular immunity, we have not yet defined those parameters that have a role in controlling the spread of HIV infection. This review discusses the basis of our understanding of HIV-specific cellular immunity and identifies its shortcomings. Furthermore, potential protective characteristics will be proposed that may ultimately be required for an effective vaccine designed to stimulate cellular immunity against HIV-1.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16989631     DOI： 10.1586/14760584.5.4.505

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN： 1476-0584            Impact factor:   5.217


  18 in total

Review 1.  Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?

Authors:  Amy B Heimberger; John H Sampson
Journal:  Neuro Oncol       Date:  2010-12-10       Impact factor: 12.300

2.  Cyclosporin A and tacrolimus reduce T-cell polyfunctionality but not interferon-γ responses directed at cytomegalovirus.

Authors:  Stephan Fuhrmann; Raskit Lachmann; Mathias Streitz; Roland Hetzer; Hans-Dieter Volk; Hans Lehmkuhl; Florian Kern
Journal:  Immunology       Date:  2012-08       Impact factor: 7.397

3.  Natural killer cells that respond to human immunodeficiency virus type 1 (HIV‐1) peptides are associated with control of HIV‐1 infection.

Authors:  Caroline T Tiemessen; Sharon Shalekoff; Stephen Meddows-Taylor; Diana B Schramm; Maria A Papathanasopoulos; Glenda E Gray; Gayle G Sherman; Ashraf H Coovadia; Louise Kuhn
Journal:  J Infect Dis       Date:  2010-11-01       Impact factor: 5.226

4.  AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells.

Authors:  Federico Mingozzi; Janneke J Meulenberg; Daniel J Hui; Etiena Basner-Tschakarjan; Nicole C Hasbrouck; Shyrie A Edmonson; Natalie A Hutnick; Michael R Betts; John J Kastelein; Erik S Stroes; Katherine A High
Journal:  Blood       Date:  2009-06-08       Impact factor: 22.113

5.  Functional proteome of macrophage carried nanoformulated antiretroviral therapy demonstrates enhanced particle carrying capacity.

Authors:  Andrea L Martinez-Skinner; Ram S Veerubhotla; Han Liu; Huangui Xiong; Fang Yu; JoEllyn M McMillan; Howard E Gendelman
Journal:  J Proteome Res       Date:  2013-04-17       Impact factor: 4.466

Review 6.  Recombinant Mycobacterium bovis BCG as an HIV vaccine vector.

Authors:  Rosamund Chapman; Gerald Chege; Enid Shephard; Helen Stutz; Anna-Lise Williamson
Journal:  Curr HIV Res       Date:  2010-06       Impact factor: 1.581

7.  Gamma/Delta T cell mRNA levels decrease at mucosal sites and increase at lymphoid sites following an oral SIV infection of macaques.

Authors:  David A Kosub; Andre Durudas; Ginger Lehrman; Jeffrey M Milush; Christopher A Cano; Mamta K Jain; Donald L Sodora
Journal:  Curr HIV Res       Date:  2008-11       Impact factor: 1.581

8.  Complement as an endogenous adjuvant for dendritic cell-mediated induction of retrovirus-specific CTLs.

Authors:  Zoltán Bánki; Wilfried Posch; Asim Ejaz; Verena Oberhauser; Suzanne Willey; Christoph Gassner; Heribert Stoiber; Ulf Dittmer; Manfred P Dierich; Kim J Hasenkrug; Doris Wilflingseder
Journal:  PLoS Pathog       Date:  2010-04-29       Impact factor: 6.823

9.  Virological outcome after structured interruption of antiretroviral therapy for human immunodeficiency virus infection is associated with the functional profile of virus-specific CD8+ T cells.

Authors:  Marybeth Daucher; David A Price; Jason M Brenchley; Laurie Lamoreaux; Julia A Metcalf; Catherine Rehm; Elizabeth Nies-Kraske; Elizabeth Urban; Christian Yoder; Diane Rock; Julie Gumkowski; Michael R Betts; Mark R Dybul; Daniel C Douek
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

Review 10.  Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.

Authors:  John H Sampson; Gary E Archer; Duane A Mitchell; Amy B Heimberger; Darell D Bigner
Journal:  Semin Immunol       Date:  2008-06-09       Impact factor: 11.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.